GlassScriptPhysician profile
Roy A Rubenstein
NPI 1679514228
$1,913.40
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $952 · 2020: $447 · 2021: $314 · 2022: $200.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $449.99 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $440.08 | 2019-2021 | |
| Glaxosmithkline, LLC. | $401.29 | 2019-2021 | |
| Genentech USA, INC. | $216.02 | 2019-2020 | |
| Boston Scientific Corporation | $109.30 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $96.99 | 2019-2020 | |
| Philips North America LLC | $85.88 | 2019-2020 | |
| Grifols USA, LLC | $69.22 | 2019-2021 | |
| Circassia INC. | $16.37 | 2019 | |
| Mylan Specialty L.P. | $16.36 | 2020 | |
| Pfizer INC. | $11.90 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Rubenstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.